



Australian Government
IP Australia

CERTIFICATE OF GRANT STANDARD PATENT

Patent number: 2017397418

The Commissioner of Patents has granted the above patent on 26 August 2021, and certifies that the below particulars have been registered in the Register of Patents.

Name and address of patentee(s):

CIC Fund Securitisation S.A. of 22-24, Boulevard Royal L-2449 Luxembourg Luxembourg

Title of invention:

Catheter system for continuous irrigation

Name of inventor(s):

McIntyre, Matthew G.

Term of Patent:

Twenty years from 6 April 2017

Priority details:

Number
62/454,829

Date
5 February 2017

Filed with
US



Dated this 26th day of August 2021

Commissioner of Patents

PATENTS ACT 1990

The Australian Patents Register is the official record and should be referred to for the full details pertaining to this IP Right.

**(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE**

(11) Application No. AU 2017397418 B2

(54) Title
Catheter system for continuous irrigation

(51) International Patent Classification(s)
A61M 25/00 (2006.01) **A61M 25/04** (2006.01)

(21) Application No: **2017397418** (22) Date of Filing: **2017.04.06**

(87) WIPO No: WO18/144045

(30) Priority Data

(31) Number (32) Date (33) Country
62/454,829 **2017.02.05** **US**

(43) Publication Date: 2018.08.09

(44) Accepted Journal Date: 2021.05.13

(71) Applicant(s)
CIC Fund Securitisation S.A.

(72) Inventor(s)
McIntyre, Matthew G.

(74) Agent / Attorney
Spruson & Ferguson, GPO Box 3898, Sydney, NSW, 2001, AU

(56) Related Art
FR 1280481 A
US 3981299 A
US 5269755 A
US 5417657 A
US 2016/0367747 A1

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
09 August 2018 (09.08.2018)



(10) International Publication Number

WO 2018/144045 A1

(51) International Patent Classification:
A61M 25/00 (2006.01) *A61M 25/04* (2006.01)

(74) Agent: CHAMBERLAIN, Christina; Intellectual Property Consulting, L.L.C., 334 Carondelet Street, Suite B, New Orleans, LA 70130 (US).

(21) International Application Number:
PCT/US2017/026450

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(22) International Filing Date:
06 April 2017 (06.04.2017)

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/454,829 05 February 2017 (05.02.2017) US

(71) Applicant: INNOMEDTWO, LLC [US/US]; 3939 Airport Boulevard, #1, Mobile, AL 36608 (US).

(72) Inventor: MCINTYRE, Matthew, G.; 5720 Riverview Plantaiton Dr., Theodore, AL 36592 (US).

(54) Title: CATHETER SYSTEM FOR CONTINUOUS IRRIGATION




FIG. 4A




FIG. 4B

(57) Abstract: An indwelling urinary catheter system having an elongated tubular catheter body 401 having a distal end and a proximal end; at least one sleeve portion 406 constructed out of a semi-permeable membranes surrounding at least one portion of the catheter body; at least one lumen to instill fluid into the catheter body; and a means to continuously efflux the instilled fluid through the semi-permeable membrane for circumferential egress of fluid out of the membrane around the catheter body. The catheter may further include a drainage lumen 414 extending through the catheter body from just short of the distal end to the proximal end and an opening or eyelet 405 in the catheter body just short of the distal end of the catheter body to permit urine to drain from a patient's bladder into the drainage lumen. A retaining mechanism may also be comprised.



TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*

Patent Cooperation Treaty Patent Application**TITLE:** CATHETER SYSTEM FOR CONTINUOUS IRRIGATION**INVENTOR(S):** MATTHEW G. MCINTYRE**[0001] RELATED APPLICATIONS**

[0002] This application claims priority to U.S. Provisional Application No. 62/454,829 filed February 5, 2017. The entire contents of the above application are hereby incorporated by reference as though fully set forth herein.

[0003] FIELD

[0004] The present invention pertains to a catheter, and more particularly, to intra-urethral or indwelling catheters capable of effluxing fluids.

[0005] BACKGROUND

[0006] The traditional Foley-type catheter is well known in the art and comprises an inflatable balloon disposed within the patient's bladder and a discharge tube extending through the urethra to the exterior. The Foley-type catheter provides passive urinary drainage, and the ability to clamp the catheter closed at a location exterior of the patient.

[0007] Urethral catheters, such as Foley-catheters, are used to drain urine from the bladder. A urinary tract infection (also called "UTI") is an infection in the urinary system, which includes the bladder and kidneys. When a urinary catheter is inserted into the bladder, germs can migrate along the catheter and cause an infection in the bladder or kidney; resulting in a catheter-associated urinary tract infection (or "CAUTI"). CAUTIs are the most common of hospital-acquired infections. In fact, 40% of all nosocomial

infections and over 100,000 admissions to hospital within the USA annually are attributable to CAUTIs.¹ Outcomes associated with CAUTIs include bacteremia and sepsis. While morbidity that is attributable to a single episode of catheterization is limited, the high frequency of catheter use (around 25% of hospitalized patients) means that the cumulative burden of CAUTIs on patients and hospitals is substantial.²

[0008] When sterile urinary catheters are inserted into the bladder, components in urine, blood, or surrounding tissue, such as polysaccharides, ions, and glycoproteins, are deposited on the surface of the device allowing the formation of biofilms. Biofilms are highly structured and actively growing bacterial communities that consist of multiple bacterial layers protected by a thick exopolysaccharide layer³. Biofilms are resistant to antibiotics/antimicrobials due to the fact that these agents cannot penetrate sufficiently through the exopolysaccharide layer.

[0009] According to Centers for Disease Control and Prevention (CDC), there was no change in overall catheter-associated urinary tract infections (CAUTI) rates between 2009 and 2014. (see <https://www.cdc.gov/hai/surveillance/>). This is not surprising, as while a variety of approaches for prevention of biofilm formation include the use of biocoatings, impregnating materials with antibiotics, antimicrobials or other

¹ D. Cardo et al. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am. J. Infect. Control, 32 (2004), pp. 470–485.

² Lo, E. et al. (2008). Strategies to Prevent Catheter- Associated Urinary Tract Infections in Acute Care Hospitals. *Infection Control and Hospital Epidemiology*, 29(S1), S41-S50. doi:10.1086/591066

³ Tenke, P.; Koves, B.; Nagy, K.; Hultgren, S.J.; Mendling, W.; Wullt, B.; Grabe, M.; Wagenlehner, F.M.; Cek, M.; Pickard, R.; et al. Update on biofilm infections in the urinary tract. *World J. Urol.* 2012, 30, 51–57.

materials as well as catheters capable of eluting antibiotics and/or antimicrobials have been used, none have been fully effective. Further, one of the major complications associated with antibiotic based coatings is the development of resistance. For example, one approach has been to attach active biocides such as antibiotics to biomaterial surfaces, or to impregnate them into the biomaterial itself by coating device surfaces or impregnating device surfaces with antibiotics such as ciprofloxacin, gentamicin, norfloxacin, and nitrofurazone. When used in clinical studies, the uncontrolled release profiles of the drugs resulted in the elution of initial high local concentrations that may initially damage the cells followed by concentrations that are not inhibitory.⁴ By not killing all of the bacteria effectively, any subsequent infection will be more difficult to eradicate due to the development of resistance.

[00010] Looking at the physiology of the urethra, UTIs are generally avoided because the act of urination (voiding) flushes everything, including bacteria. Further, there are glands in urethra that secretes protecting mucus. Several drug eluting urinary catheters are known in the prior art. Drug-eluting urinary catheters generally consist of three parts - the catheter tube, a polymer coating that binds the drug to the tube and releases the drug. The drug is slowly and continuously released into the bladder or along urethra; however, there is no continual washing of the periurethral space, where bacteria adhere, form biofilms and result in bacterial infections.

⁴ Walder, B.; Pittet, D.; Tramer, M.R. Prevention of bloodstream infections with central venous catheters treated with anti-infective agents depends on catheter type and insertion time: Evidence from a meta-analysis. Infect. Control Hosp. Epidemiol. 2002, 23, 748–756.

[00011] It would therefore be useful to magnify the effect of the glands in the urethra that protect from infection in the context of catheters.

[00012] **BRIEF SUMMARY OF THE INVENTION**

[00013] It is therefore one object of the present invention to provide an indwelling urinary catheter system having (1) an elongated tubular catheter body having a distal end and a proximal end; (2) at least one sleeve portion constructed substantially out of a semipermeable membranes surrounding at least one portion of the catheter body; (3) at least one lumen to instill fluid into the catheter body; and (4) a means to continuously efflux the instilled fluid through the semipermeable membrane of at least one sleeve resulting in the circumferential egress of fluid out of the semipermeable membrane around the catheter body. The catheter may further include a drainage lumen extending through the catheter body from just short of the distal end to the proximal end and an opening or eyelet in the catheter body just short of the distal end of the catheter body to permit urine to drain from a patient's bladder into the drainage lumen. The catheter body is disposed within the urethra of the patient and a retaining mechanism, such as an inflatable balloon, is disposed within the patient's bladder to retain the catheter in position. The fluid instilled into the catheter body and effluxed from the sleeve portion(s) may include, but is not limited to, antiseptics, antibiotics or antimicrobials, and/or combinations thereof to prevent biofilm formation on the exterior surface of the catheter body. The fluid may also include certain therapeutic agents used in intravesical therapy, such as immunotherapy agents or chemotherapeutic agents. The fluid may also include agents for patient comfort, such as antispasmodics and pain medicines. All such agents

can be effluxed directly into the bladder through the semipermeable sleeve portion around the catheter tip placed within the bladder.

[00014] It is another object of the present invention to provide different embodiments of the urinary catheter system that match the particular anatomical characteristics of a patient with respect to male or female anatomy. For example, a retention collar may be positioned on the catheter body for female patients or a space may be provided for the prostate for male patients.

[00015] **BRIEF DESCRIPTION OF THE DRAWINGS**

[00016] **Figure 1.** Figure 1 is cross section view of a traditional catheter for insertion into the bladder.

[00017] **Figure 2.** Figure 2 is a front perspective view of a traditional 2-way urinary catheter.

[00018] **Figure 3.** Figure 3 is a front perspective view of a traditional 3-way urinary catheter with a cutaway cross section of the catheter body.

[00019] **Figure 4A.** Figure 4A is a front perspective view of one embodiment of the urinary catheter of the present invention with a cutaway cross section of the catheter body.

[00020] **Figure 4B.** Figure 4B is a front perspective view of one embodiment of the urinary catheter of the present invention with a cutaway cross section of the sleeve section.

[00021] **Figure 5A.** Figure 5A is a front perspective view of an alternative embodiment of the urinary catheter of the present invention with a cutaway cross section of the catheter body.

[00022] **Figure 5B.** Figure 5B is a front perspective view of an alternative embodiment of the urinary catheter of the present invention with a cutaway cross section of the sleeve.

[00023] **Figure 6A.** Figure 6A is a front perspective view of an alternative embodiment of the urinary catheter of the present invention with a cutaway cross section of the catheter body.

[00024] **Figure 6B.** Figure 6B is a front perspective view of an alternative embodiment of the urinary catheter of the present invention with a cutaway cross section of the sleeve.

[00025] **Figure 7A.** Figure 7A is a cross section view of the placement of a catheter in a male.

[00026] **Figure 7B.** Figure 7B is a cross section view of the placement of a catheter in a female.

[00027] **Figure 8A.** Figure 8A is a front perspective view of one embodiment of the present invention for use in female patients.

[00028] **Figure 8B.** Figure 8B is a front perspective view of one embodiment of the present invention for use in female patients with a cutaway cross section of the sleeve.

[00029] **Figure 9A.** Figure 9A is a front perspective view of one embodiment of the present invention for use in male patients.

[00030] **Figure 9B.** Figure 9B is a front perspective view of one embodiment of the present invention for use in male patients with a cutaway cross section of the sleeve.

[00031] **Figure 10A.** Figure 10A is a front perspective view of one embodiment of the present invention with a couvelaire tip.

[00032] **Figure 10B.** Figure 10B is a front perspective view of one embodiment of the present invention with a dufour tip.

[00033] **Figure 10C.** Figure 10C is a front perspective view of one embodiment of the present invention with a coude tip.

[00034] **Figure 11A.** Figure 11A is a front perspective view of an alternative embodiment of the present invention with a couvelaire tip.

[00035] **Figure 11B.** Figure 11B is a front perspective view of an alternative embodiment of the present invention with a dufour tip.

[00036] **Figure 11C.** Figure 11C is a front perspective view of an alternative embodiment of the present invention with a coude tip.

[00037] **Figure 12A.** Figure 12A is a front perspective view of an alternative embodiment of the present invention with a couvelaire tip.

[00038] **Figure 12B.** Figure 12B is a front perspective view of an alternative embodiment of the present invention with a dufour tip.

[00039] **Figure 12C.** Figure 12C is a front perspective view of an alternative embodiment of the present invention with a coude tip.

[00040] **DETAILED DESCRIPTION**

[00041] For the purposes of the present invention, the term “semipermeable” is intended to encompass not only those materials that are semipermeable by their nature (i.e. those that allow certain substances to pass through it while not allowing other materials to pass through it) but materials that may be made semipermeable by creating

pores of a predetermined size that would allow certain substances to pass through it while not allowing other materials to pass through it.

[00042] Turning to the drawings, there shown in Fig. 1 is a traditional catheter for insertion into a cavity, duct, or a vessel to permit injection or withdrawal of fluids into or from the cavity, duct, or vessel, or to establish patency of a passageway. For example, the catheter body **16** may be inserted through a patient's urethra and into the patient's bladder **10** for draining urine from the bladder and/or instilling fluid into the bladder through slots in the tip **12** of the catheter. A retaining device, such as the balloon **14**, is used to maintain placement of the catheter in the bladder.

[00043] Turning to Fig. 2, a traditional 2-way urinary catheter is represented with a catheter body **201** having a distal end **202** and a proximal end **203** with the catheter body **201** connecting an opening or eyelet **204** at the distal end **202** to a drainage lumen **205** at the proximal end **203** of the catheter body **201** through which fluid may flow into the drainage lumen **205** when the catheter is used to drain fluid from the bladder. An inflatable tube section **206** with an inflation lumen **207** extends along the length of the catheter body **201** and communicates with the inflatable tube section **206**. Inflation fluid, such as distilled water, is passed through inflation lumen **207** into the tube section **206** to inflate the tube section **206**, and the inflation fluid is withdrawn from the tube section **206** into and through the inflation lumen **207** when it is desired to deflate the tube section **206**.

[00044] Turning to Fig. 3, a traditional 3-way urinary catheter is represented that is essentially the same as the catheter shown in Fig. 2, except it includes an instillation lumen **309** that extends from the catheter body **301** at the proximal end **303**. The fluid

instilled into the catheter body **301** is passed through tube **311** in the catheter body **301** and into the bladder through the opening or eyelet **304** and then the fluid is subsequently drained through the opening or eyelet **308** through tube **312** in the catheter body **301** and out the drainage lumen **305**. As shown in the cross section, the fluid instilled into the catheter body **301** passes through tube **311** in the catheter body. Inflation fluid is passed through inflation lumen **307** and through tube **310** to inflate the tube section **306**. Fluid that is drained through eyelet **308** at the distal end **302** passes through tube **312** and out the drainage lumen **305**.

[00045] Referring to Fig. 4A, the catheter of the present invention includes an elongated tubular catheter body **401** having a distal end **402** and a proximal end **403**. A drainage lumen **404** extends through tube **414** in the catheter body **401** from the distal end **402** to the proximal end **403**. The drainage lumen **404** communicates with an opening or eyelet **405** in the catheter body **401** at the distal end **402** of the catheter body **401** through which the fluid may flow into the drainage lumen **404** when the catheter is used to drain a fluid from a cavity, duct, or vessel (e.g., draining urine from a person's bladder). A sleeve portion **406** constructed from a semipermeable membrane is formed over the catheter body **401**. An instillation lumen **410** extends from the catheter body **401** at the proximal end **403**. The instillation lumen **410** connects with the sleeve portion **406** using tube **413** that runs through the length of the catheter body **401**. The fluid instilled into the catheter body **401** through the tube **413** is continuously effluxed from the sleeve portion **406** through the semipermeable membrane in a circumferential controlled delivery to continuously irrigate the periurethral space and the catheter body **401** to prevent formation of biofilm and further ensuing bacterial infection. The fluid may include, but is

not limited to, antiseptics, antibiotics or antimicrobials and/or combinations thereof to prevent biofilm formation on the exterior surface of the catheter body. Inflation fluid is passed through inflation lumen **409** and through tube **412** in the catheter body **401** to inflate the tube section **408**.

[00046] Turning to Fig. 4B, a cross section cutaway of the sleeve portion **406** illustrates that the sleeve circumferentially surrounds the catheter body **401**. In the preferred embodiment, the sleeve **406** is manufactured as a continuous part over the catheter body **401**. It may be secured to the catheter body **401** using methods known in the art such as adhesive attachment or heat press melting. Additionally, the sleeve **406** is preferably constructed from a non-elastic material to allow the effluxed fluid to irrigate the periurethral space without putting pressure on the urethra. In the preferred embodiment, the fluid effluxed from the sleeve **406** exits through the urethral opening and may be collected by a sponge or padded surface. Ideally around 300-500mL of fluid a day would be effluxed resulting in a collection rate in the sponge or padded surface of about 20ccs per hour. This is manageable in a hospital care setting with intermittent replacement of the sponge or padded surface.

[00047] Referring to Fig. 4A, the preferred embodiment a retaining mechanism near the distal end **402** of the catheter body **401** is generally an inflatable tube section **408** with an inflation lumen **409** that extends the length of the catheter body **401** through tube **412** and communicates with the inflatable tube section **408**. Inflation fluid, such as distilled water, is passed through inflation lumen **409** into the tube section **408** to inflate the tube section **408**, and the inflation fluid is withdrawn from the tube section **408** into and through the inflation lumen **409** when it is desired to deflate the tube section **408**.

When the inflatable tube section **408** is not inflated, it lies substantially parallel along the central axis of the catheter body **401**, forming a cylinder having a diameter that substantially matches the outer diameter of the catheter body **401**.

[00048] The fluid instilled into the catheter body **401** and effluxed out of the semipermeable membrane sleeve **406** of the catheter body may be pushed through the device using various mechanisms, including but not limited to, a pressure and flow regulating valve to control rate of flow for a specific fluid at a specific pressure that is installed at the effluxing instillation lumen **410** or using a pump tension device, such as a plastic ball that is blown up and then pushes fluid out at a constant rate. It is also contemplated that an intravenous (IV) pump operating at a continuous rate may also be used to move fluid through the instillation lumen **410** and out of the semipermeable membrane of the sleeve portion **406**. Again, the rate would be predetermined based on the semipermeable membrane material as well as the molecular weight cut off (MWCO) of the agent instilled into the catheter and effluxed through the semipermeable membrane to ensure that the agent is being pushed with sufficient pressure and at a sufficient rate to effectively continuously wash the periurethral space around the catheter body **401**.

[00049] It is further contemplated that a drug eluting portion could be located within the tip **411** of catheter body **401** that goes into the bladder that could be used to deliver drugs to the bladder itself, such as an antispasmodic, pain medicines, antibiotics, antiseptics, antimicrobials and combinations thereof.

[00050] Turning to Fig. 5A, an alternative embodiment of the present invention is represented with an elongated tubular catheter body **501** having a distal end **502** and a proximal end **503**. A drainage lumen **504** extends through tube **513** in the catheter body

501 from the distal end **502** to the proximal end **503**, and the drainage lumen **503** communicates with an opening or eyelet **505** in the catheter body **501** at the distal end **502** of the catheter body **501** through which the fluid may flow into the drainage lumen **504** when the catheter is used to drain a fluid from a cavity, duct, or vessel (e.g., draining urine from a person's bladder). The retaining mechanism in this example is an inflatable tube section **507** with an inflation lumen **508** that extends though the length of the catheter body **501** though tube **511** and communicates with the inflatable tube section **507**. Inflation fluid, such as distilled water, is passed through inflation lumen **508** into the tube section **507** to inflate the tube section **507**, and the inflation fluid is withdrawn from the tube section **507** into and through the inflation lumen **508** when it is desired to deflate the tube section **507**. When the inflatable tube section **507** is not inflated, it lies substantially parallel along the central axis of the catheter body **501**, forming a cylinder having a diameter that substantially matches the outer diameter of the catheter body **501**.

[00051] A sleeve portion **506** constructed from a semipermeable membrane is formed over the catheter body **501** above the tube section **507**. An instillation lumen **509** extends from the catheter body **501** at the proximal end **504**. The instillation lumen **509** connects with the sleeve portion **506** using tube **512** that runs through the length of the catheter body **501**. The fluid instilled into the catheter body **501** through the tube is continuously effluxed from the sleeve portion **506** through the semipermeable membrane and into the bladder.

[00052] Turning to Fig. 5B, a cross section cutaway of the sleeve portion **506** illustrates that the sleeve circumferentially surrounds the catheter body **501**. In the preferred embodiment, the sleeve **506** is manufactured as a continuous part over the

catheter body **501**. It may be secured to the catheter body **501** using methods known in the art such as adhesive attachment or heat press melting. The fluid effluxed through the sleeve **506** includes, but is not limited to, certain therapeutic agents used in intravesical therapy, such as immunotherapy agents or chemotherapeutic agents, as well as antispasmodic agents and numbing agents such as lidocaine. The semipermeable membrane of the sleeve **506** allows certain substances to pass through it but not others, such as allowing fluids to efflux out of the sleeve **506** but not allowing bacteria or other contaminants into the sleeve **506**. The semipermeable membrane also allows the use of a small amount of fluid everywhere circumferentially along the length of the catheter body portion in the bladder as well as into the bladder space. The pore size of the semipermeable membrane is predetermined based on the agent instilled into the catheter and effluxed from the semipermeable membrane to ensure that the agent may pass through the semipermeable membrane of the sleeve **506** and may be effluxed with sufficient pressure and at a sufficient rate to effectively continuously wash the bladder with the fluid. This method is a superior mechanism to deliver therapies such as antispasmodic agents and numbing agents than an instillation performed using a traditional catheter. With a traditional catheter, instillations are performed on an intermittent basis wherein the medicine is delivered through a single lumen catheter and then removed. The patient then voids the bladder to remove the medicine. The present invention allows the medicine to be slowly effluxed into the bladder at a continuous rate. This is especially useful after transurethral surgery on a patient. The catheter of the present invention can be placed shortly after surgery so that a drug, such as an

antispasmodic or pain medication, may be effluxed from the sleeve **506** for the next four to six hours, resulting in steady patient pain and discomfort management.

[00053] The fluid instilled into the catheter body and effluxed out of the semipermeable membrane of the sleeve portion **506** over the catheter body **501** and into the bladder may be pushed through the device using various mechanisms, including but not limited to, a pressure and flow regulating valve to control rate of flow for a specific fluid at a specific pressure that is installed at the effluxing instillation lumen port **510** or using a pump tension device, such as a plastic ball that is blown up and it then pushes fluid out at a constant rate. It is also contemplated that an intravenous (IV) pump operating at a continuous rate may also be used to move fluid through the instillation lumen and out of the semipermeable membrane of the sleeve portion **506**. Again, the rate would be predetermined based on the agent instilled into the catheter and effluxed from the semipermeable membrane to ensure that the agent is being pushed with sufficient pressure and at a sufficient rate to effectively continuously wash the bladder space.

[00054] Turning to Figs. 6A-B, another embodiment of the present invention uses both sleeve portions of Figs. 4-5. This results in a 4 way catheter capable of both effluxing fluid to continuously irrigate the periurethral space as well as effluxing fluid to continuously wash the bladder space.

[00055] As shown in Fig. 6A an elongated tubular catheter body **601** having a distal end **602** and a proximal end **603**. A drainage lumen **604** extends through tube **617** in the catheter body **601** from the distal end **602** to the proximal end **603**, and the drainage lumen **604** communicates with an opening or eyelet **605** in the catheter body **601** at the distal end **602** of the catheter body **601** through which the fluid may flow into

the drainage lumen **604** when the catheter is used to drain a fluid from a cavity, duct, or vessel (e.g., draining urine from a person's bladder). A first sleeve portion **606** constructed from a semipermeable membrane is formed over the catheter body **601**. An instillation lumen **607** extends from the catheter body **601** at the distal end **602**. The instillation lumen **607** connects with the first sleeve portion **606** using tube **616** that runs through the length of the catheter body **601**. The fluid instilled into the catheter body **601** through the tube is continuously effluxed from the sleeve portion **606** through the semipermeable membrane in a circumferential controlled delivery to continuously irrigate the periurethral space and the catheter body **601** to prevent formation of biofilm and further ensuring bacterial infection. The fluid may include, but is not limited to, antiseptics, antibiotics or antimicrobials and/or combinations thereof to prevent biofilm formation on the exterior surface of the catheter body.

[00056] A second sleeve portion **609** constructed from a semipermeable membrane is formed over the catheter body **601** above the tube section **610**. An instillation lumen **611** extends from the catheter body **601** at the distal end **602**. The instillation lumen **611** connects with the sleeve portion **609** using tube **618** that runs through the length of the catheter body **601**. The fluid instilled into the catheter body **601** through the tube **618** is continuously effluxed from the sleeve portion **609** through the semipermeable membrane and into the bladder itself.

[00057] The fluid effluxed through the sleeve **609** includes, but is not limited to, certain therapeutic agents used in intravesical therapy such as immunotherapy agents or chemotherapeutic agents, antispasmodic agents and numbing agents, such as lidocaine.

[00058] The fluid instilled into the catheter body and effluxed out of the semipermeable membrane of the sleeve portions **606** and **609** may be pushed through the device using various mechanisms, including but not limited to, pressure and flow regulating valves to control rate of flow for a specific fluid at a specific pressure that is installed at the effluxing instillation lumen ports **607** and **611**, or using a pump tension device, such as a plastic ball that you blow up and it then pushes fluid out at a constant rate. It is also contemplated that an intravenous (IV) pump operating at a continuous rate may also be used to move fluid through the instillation lumens **607** and **611** and out of the semipermeable membrane of the sleeve portions **606** and **609**, respectively. Again, the rate would be predetermined based on the agent instilled into the catheter and effluxed from the semipermeable membrane to ensure that the agent is being pushed with sufficient pressure and at a sufficient rate to effectively continuously wash the periurethral and bladder spaces.

[00059] Turning to Fig. 6B, a cross section cutaway of the sleeve portions **606** and **609** illustrates that the sleeve circumferentially surrounds the catheter body **601**. In the preferred embodiment, the sleeve portions **606** and **609** are manufactured as continuous parts over the catheter body **601**. They may be secured to the catheter body **601** using methods known in the art such as adhesive attachment or heat press melting.

[00060] Turning to Fig. 7A-B, the differences in anatomy for the placement of a urinary catheter are shown. The male anatomy of Fig. 7A results in a larger portion of the catheter body in the periurethral space than the female counterpart. Fig. 7A shows the bladder **701**, rectum **702**, pubic bone **703**, prostate **704**, urethra **705** and the catheter **706**.

The catheter **706** must also be fed past the prostate **704** in males before it can be retained in the bladder **701**. The female anatomy of Fig. 7B results in a shorter portion of the catheter body needed to fill the periurethral space. Fig. 7B shows the bladder **707**, rectum **708**, pubic bone **709**, vagina **710**, urethra **711** and catheter **712**.

[00061] Taking these anatomical differences into consideration, Fig. 8A-B shows the distal end of the catheter of Fig. 4 as used for female anatomy whereas Fig. 9A-B shows the distal end of the catheter of Fig. 5 as used for male anatomy. The sleeve portion **801** of Fig. 8A-B is shorter than the sleeve portion **901** of Fig. 9A-B. Additionally, there is a larger space **903** between the sleeve portion **901** and the inflatable portion **902** than the space **803** between the sleeve portion **801** and the inflatable portion **802**, which accommodates placement of the catheter in the presence of the prostate.

[00062] As shown in Figs. 10A-C, one embodiment of the invention shown in Figs. 4A-B with sleeve portion **1001**, catheter body **1002**, retaining device **1003**, drainage eyelet **1004** and alternative instillation eyelet **1005** may have various shapes to the end that is inserted into the bladder. For example, Fig. 10 A shows a couvelaire tip, Fig. 10B shows a dufour tip and Fig. 10C shows a coude tip.

[00063] As shown in Figs. 11A-C, one embodiment of the invention shown in Figs. 5A-B with sleeve portion **1006**, catheter body **1002**, retaining device **1003**, drainage eyelet **1004** and alternative instillation eyelet **1005** may have various shapes to the end that is inserted into the bladder. For example, Fig. 11 A shows a couvelaire tip, Fig. 11B shows a dufour tip and Fig. 11C shows a coude tip.

[00064] As shown in Figs. 12A-C, one embodiment of the invention shown in Figs. 6A-B with sleeve portions **1001** and **1006**, catheter body **1002**, retaining device

1003, drainage eyelet **1004** and alternative instillation eyelet **1005** may have various shapes to the end that is inserted into the bladder. For example, Fig. 12 A shows a couvelaire tip, Fig. 12B shows a dufour tip and Fig. 12C shows a coude tip.

[00065] It is necessary for the fluid to be effluxed continuously at a basal rate to effect the continual washing of the periurethral space, where bacteria adhere, to prevent formation of biofilms and resulting bacterial infections. However, it is also contemplated that the fluid may be continuously effluxed from the semipermeable membrane(s) in a peristaltic wave action along the length of the catheter body in addition to the basal rate.

[00066] For the purposes of promoting an understanding of the principles of the invention, reference has been made to the preferred embodiments illustrated in the drawings, and specific language has been used to describe these embodiments. However, this specific language intends no limitation of the scope of the invention, and the invention should be construed to encompass all embodiments that would normally occur to one of ordinary skill in the art. The particular implementations shown and described herein are illustrative examples of the invention and are not intended to otherwise limit the scope of the invention in any way. For the sake of brevity, conventional aspects of the method (and components of the individual operating components of the method) may not be described in detail. Furthermore, the connecting lines, or connectors shown in the various figures presented are intended to represent exemplary functional relationships and/or physical or logical couplings between the various elements. It should be noted that many alternative or additional functional relationships, physical connections or logical connections might be present in a practical device. Moreover, no item or component is essential to the practice of the invention unless the element is specifically described as

“essential” or “critical”. Numerous modifications and adaptations will be readily apparent to those skilled in this art without departing from the spirit and scope of the present invention.

CLAIMS

1. A urinary catheter assembly comprising:

an elongate catheter body having a proximal end and a distal end,
a first sleeve portion comprising a semipermeable membrane, wherein the first sleeve portion is disposed on an outer surface of at least one portion of the catheter body;
and;

an inflation lumen at the proximal end of the catheter body, wherein the inflation lumen is in fluid communication with an inflatable tube section; wherein an inflation fluid is passed through an inflation lumen, and a through tube in the catheter body to inflate the tube section,

wherein the urinary catheter assembly further comprises:

a first instillation lumen at the proximal end of the catheter body, wherein the first instillation lumen is in fluid communication with the first sleeve portion;

a pump in fluid communication with said first instillation lumen

wherein the pump is operable to continuously move a first fluid through the first instillation lumen to the first sleeve portion and to continuously and circumferentially efflux the first fluid out of the semipermeable membrane of the first sleeve.

2. The urinary catheter assembly according to claim 1, wherein the first sleeve portion is at the tip of the distal end of the catheter body

3. The urinary catheter assembly according to claim 1 or 2, further comprising a pressure and flow regulating valve operable to regulate a flow rate and a pressure of the first fluid effluxing through the first sleeve portion.

4. The urinary catheter assembly according to claim 3, wherein the pump comprises a pump tension device operable to regulate a flow rate and a pressure of the first fluid effluxing through the first sleeve portion.

5. The urinary catheter assembly according to claim 3, wherein the pump comprises an intravenous (IV) pump operable to operate at a continuous rate and operable to regulate a flow rate and a pressure of the first fluid effluxing through the first sleeve portion.
6. The urinary catheter assembly according to any one of claims 3 to 5, wherein the flow rate and the pressure of the first fluid effluxing through the first sleeve portion is predetermined based on the material used for the semipermeable membrane of the first sleeve portion and calculated based on a molecular weight cut off (MWCO) of the first fluid.
7. The urinary catheter assembly according to any one of the preceding claims, wherein the pore size of the semipermeable membrane of the first sleeve portion is predetermined and calculated based on a molecular weight cut off (MWCO) of the first fluid.
8. The urinary catheter assembly according to any one of the preceding claims, further comprising:
 - a second sleeve portion comprising a semipermeable membrane, wherein the second sleeve portion is disposed on the outer surface of at least one portion of the catheter body;
 - a second instillation lumen at the proximal end end of the catheter body in fluid communication with the second sleeve portion; and
 - a second pump in fluid communication with said second instillation lumen; wherein the second pump is operable to continuously move a second fluid through the second instillation lumen to the second sleeve portion and to continuously and circumferentially efflux the second fluid out of the semipermeable membrane of the second sleeve portion.
9. The urinary catheter assembly according to claim 8, further comprising a second pressure and flow regulating valve operable to regulate a flow rate and a pressure of the second fluid effluxing through the second sleeve portion.
10. The urinary catheter assembly according to claim 8 or 9, wherein the second pump comprises a pump tension device operable to regulate a flow rate and a pressure of the second fluid effluxing through the second sleeve portion.

11. The urinary catheter assembly according to any one of claims 8 to 10, wherein the second pump is an intravenous (IV) pump operable to operate at a continuous rate and operable to regulate a flow rate and a pressure of the second fluid effluxing through the second sleeve portion.
12. The urinary catheter assembly according to any one of claims 8 to 11, wherein the flow rate and the pressure of the second fluid effluxing through the second sleeve portion (609) is predetermined based on the material used for the semipermeable membrane of the second sleeve portion (609) and calculated based on a molecular weight cut off (MWCO) of the second fluid.
13. The urinary catheter assembly according to any one of claims 8 to 12, wherein the pore size of the semipermeable membrane of the second sleeve portion is predetermined and calculated based on the molecular weight cut off (MWCO) of the second fluid.
14. The urinary catheter assembly according to any one of claims 8 to 13, further comprising a retaining mechanism towards the distal end of the catheter body.
15. The urinary catheter assembly according to claim 14, wherein the first sleeve portion is between the proximal end of the catheter body and the retaining mechanism.
16. The urinary catheter assembly according to claim 14 or 15, wherein the second sleeve portion is between the distal end of the catheter body and the retaining mechanism.
17. The urinary catheter assembly according to any one of claims 14 to 16, wherein the first sleeve portion is at the tip of the distal end of the catheter body and the second sleeve portion is located between the proximal end of the catheter body and the retaining mechanism.
18. The urinary catheter assembly according to any one of the preceding claims, further comprising a drainage lumen and at least one drainage opening at the distal end of the catheter body, wherein the drainage lumen extends through the catheter body and is in fluid communication with the at least one drainage opening.

1/17




FIG. 1

2/17




FIG. 2

3/17






FIG. 3





6/17




FIG. 5A

7/17




FIG. 5B

8/17




FIG. 6A

9/17




FIG. 6B

10/17




FIG. 7A




FIG. 7B

11/17




FIG. 8A

12/17




FIG. 8B

13/17




FIG. 9A

14/17




FIG. 9B

15/17




FIG. 10A




FIG. 10B




FIG. 10C

16/17




FIG. 11A




FIG. 11B




FIG. 11C

17/17




FIG. 12A




FIG. 12B




FIG. 12C